In the United States, an estimated 60-70 million people are affected by gastrointestinal disorders (GI). Celiac disease may be present despite the absence of GI symptoms, particularly, in relatives of individuals with CD. 1
In the U.S., 2 in 5 Americans are affected by GI disorders: up to 20% of adults in North America suffer from irritable bowel syndrome (IBS) 2, approximately 0.44% of Americans experience Crohn’s disease and Ulcerative Colitis 3, while up to 1% of the general population have symptoms of CD 4. Moreover, 15% of the general population in western countries suffer from indegestion and constipation 5, 6. Not surprisingly, there is overlap between these disorders.
The GHP is a comprehensive test profile that analyzes genetic predisposition, detects specific antibodies, and measures potentially inflammatory cellular reactions all through one simple blood draw.
Celiac disease risk analysis is determined based on the presence or absence of the HLA-DQ alleles. Both the DQ8 and DQ2.5 alleles are tested in this profile, with the DQ2.5 allele representing a much greater risk of CD.
Four specific serum antibodies are tested due to their high sensitivity and specificity for active CD. The higher the antibodies levels, the more likely untreated CD is present. Higher antibody levels indicate higher likelihood of active CD.
Anti-Saccharomyces Cerevisiae Antibody (ASCA) is tested to identify risk of Crohn’s Disease. The presence of ASCA may also reflect increased intestinal inflammation and permeability, including an association with active CD.
Gluten reactions can also be triggered by food sensitivities. The Alcat Test is included to reveal NCGS to 19 different items; including non-gluten containing items so you will know what your options are if you have a problem with gluten. The Alcat Test helps to identify food sensitivities and triggers of chronic inflammation to over 450 foods and other substances.
Option 1: GHP
Option 2: CD risk only (genetic):
GHP test results are color-coded and easy to read. Each result is thoroughly explained with physician written commentary.
Cell Science Systems, Corp. is a specialty clinical laboratory that develops and performs laboratory testing in immunology and cell bioligy supporting the personalized treatment and prevention of chronic disease. Cell Science Systems, Corp. operates a CLIA certified laboratoy and is an FDA inspected and registered, cGMP medical device manufacturer meeting ISO EN13485 2012 standards.
Cell Science Systems fulfills high quality standards in accordance with state, federal and international regulations.
1 Aggarwal S, Lebwohl B, Green PHR. Screening for celiac disease in average-risk and high-risk populations. Therap Adv Gastroenterol. 2012 Jan; 5(1): 37–47.
2 Hulisz D. The Burden of Illness of Irritable Bowel Syndrome: Current Challenges and Hope for the Future. J Manag Care Pharm. 2004;10(4):299-309
3 Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004 May;126(6):1504-17.
4 Gasbarrini GB, Mangiola F. Wheat-related disorders: A broad spectrum of ‘evolving’ diseases. United European Gastroenterol J. Aug 2014; 2(4): 254–262.
5 Saad RJ, Chey WD. Review article: current and emerging therapies for functional dyspepsia. Aliment Pharmacol Ther. 2006; 24, 475–492
6 Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. Evidence-based position statement on the management of irritable bowel syndrome in North America. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Am J Gastroenterol. 2009;104(Suppl 1):S1-S35.
